Could you be one of the estimated 3,300 patients in the United States carrying the gene variant that causes SORD Deficiency? If you have been diagnosed with CMT2 (a subtype of Charcot-Marie-Tooth disease) or distal hereditary motor neuropathy (dHMN), SORD Deficiency may be worth exploring with your physician.

Watch this webinar with Shoshana Shendelman, Founder and CEO of Applied Therapeutics, to learn more about SORD Deficiency and an investigational treatment under study at the time of this recording.

For information on current research and registry participation, visit the GRIN Registry.